FC25: New Checkpoint on the Block: The Latest Evidence for PD-L1 Inhibition in Cutaneous Squamous Cell Carcinoma: An Online Activity
Released on
January 6, 2026
Earn up to
0.25 AMA PRA Category 1 Credit™
In this short program at the 2025 Fall Clinical Dermatology Conference®, experts Dr. Rigel and Dr. Schlesinger explore the expanding therapeutic landscape for cutaneous squamous cell carcinoma (cSCC) and review an emerging mechanism targeting PD-L1. Don’t miss this opportunity to learn about the new checkpoint inhibitor in the cSCC space!
“It's an exciting time [in CSCC] for us to see. It's been a revolution in skin cancer development in treating with immunotherapy.” – Todd Schlesinger, MD
FC25: New Checkpoint on the Block: The Latest Evidence for PD-L1 Inhibition in Cutaneous Squamous Cell Carcinoma: An Online Activity
This activity is supported by an educational grant from Sun Pharmaceutical Industries Ltd.